阿托伐他汀联用雷米普利对急性冠脉综合征抗炎效应的临床研究

目的：观察阿托伐他汀及雷米普利对急性冠脉综合征（ACS）时血脂、血清C-反应蛋白（CRP）水平的影响。方法：随机将ACS患者分为对照组、标准剂量阿托伐他汀组、大剂量阿托伐他汀组及大剂量阿托伐他汀联用雷米普利组。分别测定治疗前及30d干预后患者血清CRP和血脂浓度的变化。结果：治疗30d后，对照组与标准剂量阿托伐他汀组血脂水平无明显降低（P〉0．05），大剂量阿托伐他汀组及大剂量阿托伐他汀联用雷米普利组血脂水平降低显著低于对照组及标准剂量阿托伐他汀组（P〈0．05）；4组ACS患者CRP水平均明显降低（P〈0．05），大剂量阿托伐他汀组及大剂量阿托伐他汀联用雷米普利组CRP水平降低显著低于对照组及标准剂量阿托伐他汀组（P〈0．05），大剂量阿托伐他汀联用雷米普利组CRP水平较大剂量阿托伐他汀组有显著降低（P〈0．05）；血清cRP水平与TC、LDL-C水平的变化无相关性。结论：ACS的发生与机体炎症反应激活有关，在ACS早期应用大剂量阿托伐他汀能迅速降低血清CRP和血脂水平，且这是一种独立于降脂作用之外的抗炎效应。

Clinic study on anti-inflammatory effects of atorvastatin associated with rampril in patients with acute coronary syndrome

Objective： To investigate the anti-inflammatory effect of atorvastatin associated with rampril in acute coronary syndromes （ACS） with C-reactive protein （CRP） reduction. Methods： Patients with ACS were assigned to four groups： control group, standard dose atorvastatin group, high dose atorvastatin group and high dose atorvastatin associated with rampril group. CRP levels and lipid profiles were measured at first and 30 days later. Results： The study suggested： （1） lipid profiles levels didn＇t alter significantly in control group and standard dose atorvastatin group （P〉0.05）, though it decreased significantly from baseline to 30 days later in high dose atorvastatin group and high dose atorvastatin associated with rampril group （P〈0. 05）. （2） CRP levels decreased significantly from baseline to 30 days later in four groups （P（0.05）. CRP levels in high dose atorvastatin group and high dose atorvastatin associated with rampril group decreased significantly versus control group and standard dose atorvastatin group （P〈0. 05）. CRP levels in high dose atorvastatin associated with rampril group decreased significantly versus high dose atorvastatin group （P〈0.05）. （3） No correlation were found between CRP levels and TC,LDL-C levels. Conclusion： CRP levels in ACS reduced rapidly after wsing atorvastatin and rampril. The study shows that atorvastatin and rampril have faster and earlier anti inflammatory effect in addition to lipid-decreasing effects in ACS.